Insights from the 2022 R&D Innovation Survey

In this playbook, we share insights from 33 biopharma executives who reported their experience using these bellwether approaches for the 2022 R&D Innovation Survey conducted by Health Advances and Parexel Biotech. This innovation snapshot shows biotechs adopting new approaches and encountering a variety of roadblocks, but pushing forward to expand their use and deliver faster, more efficient development.

Considered as a whole, findings from the December 2022 R&D Innovation Survey lead us to three top-line insights:

  1. Regulatory and commercial strategies must be considered earlier.
  2. Adaptive designs, ECAs and DCTs are growing in importance.
  3. Biopharma must pursue new ways to increase diversity in clinical trials.

Open PDF

Return to Insights Center